Researchers are making progress in efforts to combat the dangerous, often deadly, graft-versus-host disease (GVHD) that can occur after allogeneic hematopoietic cell transplantation (allo-HCT), according to several reports presented at the 2017 annual meeting of the American Society of Hematology (ASH).
The immunotherapy drug abatacept (Orencia, Bristol-Myers Squibb) added to the standard regimen nearly prevented acute GVHD during a multicenter phase 2 trial by researchers led by Leslie Kean,